398 related articles for article (PubMed ID: 24968545)
1. Prevention of thromboembolic complication in atrial fibrillation by using anticoagulants.
Wagh K; Vikhe VB; Kumar RS; Auti N; Jose M
J Assoc Physicians India; 2013 Dec; 61(12):894-5. PubMed ID: 24968545
[TBL] [Abstract][Full Text] [Related]
2. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Selçuk H; Selçuk MT; Maden O
Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
[TBL] [Abstract][Full Text] [Related]
3. Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation.
Lang NN; Connelly DT
J R Coll Physicians Edinb; 2013; 43(2):151-8. PubMed ID: 23734359
[TBL] [Abstract][Full Text] [Related]
4. The need for new oral anticoagulants in clinical practice.
Hylek EM
J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):605-9. PubMed ID: 19571764
[TBL] [Abstract][Full Text] [Related]
5. [Atrial fibrillation and thromboembolic events prevention. State of the art].
Matteoli S; Trappolini M; Chillotti FM
Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
[TBL] [Abstract][Full Text] [Related]
6. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.
Mant JW
Thromb Haemost; 2008 Jul; 100(1):14-5. PubMed ID: 18612531
[No Abstract] [Full Text] [Related]
7. [New treatments for stroke and thromboembolism prevention in atrial fibrillation].
Shiyovich A; Khalameizer V; Katz A
Harefuah; 2014 Jan; 153(1):32-8, 64. PubMed ID: 24605405
[TBL] [Abstract][Full Text] [Related]
8. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study).
Friberg L; Hammar N; Ringh M; Pettersson H; Rosenqvist M
Eur Heart J; 2006 Aug; 27(16):1954-64. PubMed ID: 16847008
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
10. Thromboembolism in atrial fibrillation.
Menke J; Lüthje L; Kastrup A; Larsen J
Am J Cardiol; 2010 Feb; 105(4):502-10. PubMed ID: 20152245
[TBL] [Abstract][Full Text] [Related]
11. Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients.
Blich M; Gross B
Int J Cardiol; 2004 Jul; 96(1):89-95. PubMed ID: 15203266
[TBL] [Abstract][Full Text] [Related]
12. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.
Al-Khatib SM; Thomas L; Wallentin L; Lopes RD; Gersh B; Garcia D; Ezekowitz J; Alings M; Yang H; Alexander JH; Flaker G; Hanna M; Granger CB
Eur Heart J; 2013 Aug; 34(31):2464-71. PubMed ID: 23594592
[TBL] [Abstract][Full Text] [Related]
14. Prevention of thromboembolic events in atrial fibrillation.
Koefoed BG; Gulløv AL; Petersen P
Thromb Haemost; 1997 Jul; 78(1):377-81. PubMed ID: 9198182
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.
Salim I; Al Suwaidi J; Ghadban W; Salam AM
Expert Opin Drug Saf; 2013 Jan; 12(1):53-63. PubMed ID: 23095103
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
[TBL] [Abstract][Full Text] [Related]
17. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
Hylek EM
Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
[No Abstract] [Full Text] [Related]
18. Anticoagulants in patients with atrial fibrillation and end-stage renal disease.
Brimble KS; Ingram AJ; Eikelboom JW; Hart RG
Postgrad Med; 2012 Nov; 124(6):17-25. PubMed ID: 23322135
[TBL] [Abstract][Full Text] [Related]
19. Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation.
Hammwöhner M; Goette A
J Cardiovasc Pharmacol; 2008 Jul; 52(1):18-27. PubMed ID: 18594479
[TBL] [Abstract][Full Text] [Related]
20. [ANMCO statement on prevention of thromboembolism in atrial fibrillation and role of the new oral anticoagulants].
Colonna P; Abrignani MG; Colivicchi F; Verdecchia P; Alunni G; Bongo AS; Ceravolo R; Oliva F; Rakar S; Riccio C; Scherillo M; Valle R; Bovenzi F;
G Ital Cardiol (Rome); 2013 Apr; 14(4):295-322. PubMed ID: 23567775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
